We source what fits; we create what's missing.
Nine stages, one chain — our edge over ordinary factories and trading companies.
What we do best is not making everything ourselves. When a mature, reliable supply exists, we source it globally and pick the best; when the market is empty or blocked, we initiate the project and develop the process, then make it in our own plants. What truly sets us apart from ordinary factories and trading companies is one integrated chain — project initiation, R&D, technology transfer, quality control, audit, registration, AI digitalization, compliance and after-sales — with our own people, standards and systems in every link.
We don't promise to do 'everything,' nor do we dress up as a capacity giant. Both sourcing and making have limits, and we state them clearly: where we can deliver, we say to what extent; where we can't, we tell you exactly where to look.
From project initiation and R&D through to sustained overseas supply, we are present on every segment of the value chain — and we hold up the middle with registration, audit, quality systems and digital governance so it does not sink.
Working back from end-market demand: feasibility, route design and process development, from lab scale to pilot scale.
Qualified capacity sourced globally, plus our own plants to carry production. We set the quality and delivery standards rather than passing them on.
Registration support, export and market compliance, overseas customer networks — and sustained supply long after the sale.
Registration, audit, quality systems and digital governance run through every stage, turning the middle manufacturing segment into a defensible one.
A typical plant guards only the middle segment; a trading company just moves goods between the two ends. We occupy the whole chain, and carry one accountability across it.
The middle segment is not doomed to thin margins: registration, audit, quality systems and digital governance hold it up and make it defensible — and integrated players earn a valuation premium.
Source or Create: Two Legs, One Integrated Chain
Our strength is not making everything ourselves. It is this: source when a qualified option exists; initiate, develop and produce in our own plants when it doesn't. The real gap is the nine-link chain below — ordinary factories can't cover the front end, ordinary trading companies can't hold the back end. We hold every link.
When a mature, reliable supply exists, we don't reinvent the wheel: we work backward from end-market demand to decide what to source, then compare globally — quotes, samples, audits — and only approve qualified suppliers.
- Global comparison: multi-source quotes, sample checks, on-site audits
- Tiered network: core plants for volume, flexible plants for gaps, labs for cross-checks
- Sourcing is not flipping: every deal is backed by technical judgment
When the market is empty, supply is blocked, or quality is unstable, we initiate the project: business case, route design, process development, scale-up — and finally produce in our own plants.
- Initiation: why this one — patent window, demand strength, technical barrier
- Process R&D: route design, lab to pilot, scale-up validation
- Our own plants produce; we set the quality and delivery standards
Sourcing is not flipping — it takes technical judgment. Making is not making anything — only what we can master. Products can be sourced; capability must be ours.
Every link has our own people, standards and systems — so nothing breaks between a rough idea and sustained after-sales supply. AI digitalization is the data backbone running through all nine.
These nine stages below are what hold up the middle of the chain.
Work backward from end-market demand; first explain why this one
Route and process development, lab scale to pilot scale
Process handover, scale-up, change control — landing the tech in the plant
Batch records, QC, deviations and CAPA, COA — quality control end to end
Supplier and quality audits: tiered qualification, annual re-audit, change notification
Registration support worldwide: DMF, CEP, linked-review dossiers
Data and AI platform throughout: intelligence, matching, quoting, delivery trail
Export and market-access compliance: documents, trade and logistics
Traceability, change notices, sustained supply — delivery is not the end
Sourcing or making, these nine links stay under one accountable party — the whole journey from a spot batch to localised production.
How we work with you: three engagement models
Three standard ways to engage, chosen by how deep you want us in. We do all three.
Hand us a product end to end — sourcing, registration, long-term supply. Our systems, our processes, our people. You track outcomes, with a single point of accountability.
Take just one function — audit, registration support, sample comparison. It runs on your systems and under your direction; we supply the specialists.
Long-term commitment for core partners: reserved capacity, joint governance, shared risk and reward, and deep embedding into your quality and compliance systems.
FSO = full-service outsourcing; FSP = functional service provider. The difference comes down to three things: bundled or unbundled, whose systems run it, and who holds the controls.
Three ways to do the same job
'Different from ordinary factories and trading companies' is not a slogan — line by line, here is the difference.
| Dimension | Ordinary factory | Ordinary trading company | Unibest |
|---|---|---|---|
| Where products come from | Only what its own lines make | Whatever the customer asks for | Source globally where possible; develop and make in-house where not |
| Initiation and R&D | Around its own portfolio | Rarely | Business cases and process R&D are routine |
| Technology transfer | Rare | Not touched | One of our three delivery tiers |
| Quality and audit | Controls its own workshop | Forwards reports | Tiered supplier network + own audits + data trail |
| Registration and compliance | Each handles a piece | Can't help | Registration support plus export and market compliance in one |
| AI digitalization | Isolated systems | Email and spreadsheets | One platform: intelligence, matching, quoting, delivery trail |
| After-sales and supply | Ends at shipment | Ends at the deal | Traceability, change notices, sustained supply |
| Accountability | One plant | One middleman | One accountable party, from a spot batch to localised production |
Business Model Canvas (one-page view)
The nine cells index this page: one line each, with the fuller explanation further down. Filled with what we actually do today — not an aspirational chart.
Named manufacturing sites in our tiered supplier network, CRO / CDMO technical partners, and registration and commercial partners across Europe and emerging markets; our Hong Kong (China) and Singapore entities handle cross-border settlement and licensing.
Initiation driven by end-market demand; global sourcing where possible, in-house development and production where not; integrated technology transfer, quality control, audit, registration and compliance; AI digitalization throughout; sustained after-sales supply.
Products can be sourced — capability must be ours: source globally where a qualified option exists, develop and produce in our own plants where none does. One integrated chain from initiation to after-sales, under one accountable party.
Trust builds in stages — first a batch, then development, then localisation. A dedicated project contact, proactive notice on changes and deviations, and no one-off transactions.
Small and mid-size formulators in Europe and emerging markets; overseas buyers who need a second source; pipeline owners seeking out-licensing and localised production.
Tiered supplier network with named-site dossiers, quality and registration documentation system, selection and intelligence database, go-global dosage database, overseas platform and settlement channels.
Website and inquiry intake, trade shows and industry events (CPhI and similar), overseas BD visits and online meetings, digital outreach and the member area.
Sourcing and manufacturing cost, quality and compliance spend (audits, testing, documentation), technical and registration staff, logistics and customs, overseas platform operations. Spend is approved per project — never a blurred pass-through to the client.
Goods price on trade supply; project fees for development and technology transfer, staged by milestone; retainer and success fees on licensing matchmaking; royalty and recurring API supply once transfer lands.
Cooperation models, responsibility and fees
One row per commercial relationship. If a project spans two models, we state it in writing before work starts.
| What you buy | Our role | Contracting and performing parties | Deliverables | Who charges, and how | When it starts |
|---|---|---|---|---|---|
Supply Material delivered to an agreed specification and quantity | Contractual supplier and exporter of record | Unibest trading entity signs; manufacturing by the named site | CoA, batch record summary, shipping and customs documents, change notification | Goods price quoted by Unibest; no separate service fee | Specification, quantity, Incoterms and target market confirmed |
Development and technology transfer A defined technical scope with acceptance criteria | Service provider under a development or transfer agreement | Unibest with the selected technical partner, both named in the agreement | Technical scope, acceptance criteria, development or transfer report, documentation package | Project fee agreed before work starts, staged by milestone | Technical review completed and scope signed off |
Licensing and localisation Introduction, coordination and negotiation support for an asset or territory | Intermediary and project coordinator, not the rights holder | Unibest as intermediary; the contract is signed between rights holder and partner | Counterparty shortlist, dossier gap list, term-sheet coordination, meeting records | Retainer and/or success fee, stated in the engagement letter | Mandate signed and asset or territory scope defined |
Paid placement or priority recommendation never replaces technical and quality fit. Candidates are ranked on specification, documentation and site capability, and the reason is shown with each one.
These three models are alternatives chosen by project need, not steps you must buy in sequence. Many buyers start with a single shipment and stop there.
Let's start with the four things you worry about most
In cross-border pharma-intermediate sourcing, the problem was never 'is there stock'—it's these four things.
Dozens of Chinese plants can make this intermediate, with quotes ranging from 800 to 3,000—and no one tells you where the gap is, or in which document.
Who issued the CoA, and was the method validated? Are batch numbers continuous? Will changes be notified? If the plant switches, do we re-run the impurity profile?
Getting the goods is only the start: export docs, registration files, cold-chain and hazardous shipping, target-market compliance—who owns it?
Five suppliers each own one slice; a plant changes staff, a lab drops the ball, lead times slip—and in the end the customer comes to you, yet you control none of it.
We offer three delivery tiers, matched to your stage of need
Not sure which tier to start at? Most clients begin with Trade, using one or two batches to gauge our reliability.
You already know the exact product and need qualified material now
- Match pre-audited suppliers to your spec and produce a tiered quotation
- Place orders against a signed quality agreement, locking batch and lead time
- Deliver full batch documentation with the goods—never just a single CoA
The material isn't in any catalog, or existing suppliers can't hit your spec
- Technical review sets the route and acceptance criteria before any work begins
- Lab trial → analytical method development & validation → impurity profile & forced degradation
- Scale-up and process validation to build a reproducible tech package
You need a second source, local production, or to pass regulatory review
- Transfer the full process and method package, reproduced to acceptance criteria
- Scale-up validation and batch-to-batch continuity confirmation
- Compilation of registration dossiers and lifecycle maintenance support
Why structure it this way? Because trust in a cross-border supply relationship is built layer by layer: first we prove we can deliver a qualified batch on time, then that we can solve a spec no one else has, and only last do we discuss handing over process and registration files. We won't pitch tech transfer on a first engagement, nor force a consulting package when you only want material.
Underpinning these three tiers are three layers of capability
In a seller's market, everyone claims to have a network and resources. We break these three layers out so you can check each one.
We don't start from 'whatever the plant has to sell.' We work back from end-market demand: which blockbusters are near their patent cliff, which generics are being filed intensively, and which critical fragments no one can make.
- LOE opportunity library: an opportunity list organized by patent cliff and critical intermediate
- Each opportunity tags the end drug, window period, critical fragment, technical barrier and supply concentration
- Conclusion before quotation—we explain 'why this one' before we discuss price
Suppliers aren't a price-comparison list—they're a tiered network: core plants for volume, flexible plants for special reactions, analytical labs for cross-checking. Technical barriers live in the process, not in the pitch.
- Core plants (long-term): quality and confidentiality agreements lock in priority capacity
- Flexible plants: small-batch custom, hazardous & highly potent reactions, special equipment
- Technical strengths: chiral synthesis & asymmetric catalysis · fluorinated and difluorinated building blocks · multi-step coupling & heterocycles · continuous flow and AI-assisted route design
This is the line that separates a 'trader' from a 'solutions partner.' QA doesn't just 'collect reports and stamp them'—it owns audits, agreements, deviations and data integrity.
- Supplier audits & quality agreements: tiering, annual re-review, critical-change notification
- Project quality loop: work order → plan → batch record → QC → deviation / CAPA → CoA → archive
- Data integrity: a unified data room retains raw spectra and batch records, supporting later due diligence and review
We do not promise end-to-end GLP safety assessment or formulation-side cGMP manufacturing, nor do we build our own bulk-chemical capacity. What we provide is supply-chain quality traceability and delivery assurance for pharmaceutical intermediates and APIs: supplier audits, quality agreements, batch documentation, deviation closure and data retention. Where responsibility for safety assessment, clinical trials or formulation registration sits elsewhere, we point clearly to qualified partners rather than glossing over it.
How an order runs end to end
From your brief to delivery, there are six fixed stages, each with a clear deliverable.
- IntakeDay 0
Product or CAS, spec & purity, quantity, target country, required documents. Captured in a structured brief—no guessing by email.
Output: Structured requirement brief - Technical reviewDay 1–3
Route feasibility, supply match and an initial screen of impurity and compliance risk. If we can do it, we say so; if not, we say so directly.
Output: Review conclusion + recommended plan - Commercial proposalDay 3–5
Tiered pricing, MOQ, lead time and quality-agreement terms—all upfront, so terms don't shift mid-talk.
Output: Quotation + draft agreement - Production & qualityPer cycle
Batch tracking, deviation & CAPA closure, QC result review; cross-checking arranged for critical projects.
Output: Batch document package - Documentation & complianceWith shipment
CoA, batch-record summary, SDS, registration support files and an export-compliance screen—delivered together.
Output: Delivery document package - Delivery & reorderOngoing
Logistics & customs follow-up, customer feedback archived, supplier scores fed back into the network.
Output: Delivery confirmation + score record
Progress and documents for steps 2–5 are visible on the platform—check anytime, instead of chasing by email.See the systematic delivery chain →
Who delivers on this
Not one person, one email or one WeChat ID—but a group structure with real entities, clear roles and defined boundaries.
Claiming nine links is not enough — each one needs a clear owner. The group structure below has four tiers, each tagged with the links it carries: every link sits with a specific tier and entity, not a slogan on the wall.
The group's holding and industrial-investment arm, consolidating outbound investment and resource allocation.
Project selection and initiation reviews are investment decisions taken here
Hong Kong and Singapore entities handle cross-border trade, licensing and settlement, connecting APAC, Europe and North America.
Registration support and export / market-access compliance are handled here
The mainland operating and import/export entities (Ningbo, Shanghai), the single point connecting global clients and order fulfillment.
Quality audits, release control and sustained after-sales supply run here
Specialized by segment—formulation MAH, API & intermediates, biologics & delivery, pharma materials, green environmental—and more.
Process R&D and technology transfer land in the segment companies and our own plants
Data and AI platform throughout: intelligence, matching, quoting, delivery trail
This is the public overview of where the nine links sit in the group structure: every link has a clear tier and entity. On-site quality work such as batch records and QC runs at the plants, under standards set by the core operating entity.
Finished-Dosage Go-Global & Technology Transfer · the T-Bond Model
Turning a buying relationship into a making relationship — carried by Shanghai Brisalus Biomedical.
China's API and finished-dosage manufacturing is globally competitive, yet technology transfer and localisation remain under-exploited. The T-Bond (Technology-Bond) model uses API-to-dosage technology transfer as the binding link between front-end supply and back-end technical service. Clients may enter at any layer; continuing down is one continuous path.
Continuous supply of advanced intermediates and API is where trust starts. While supplying, we identify the partner's local-production intent and technology-transfer needs.
We upgrade a purchasing need into a technical cooperation need — from buying intermediate to making the dosage form locally. Commercial and technical teams assess feasibility and the registration path together.
We lead the API-to-dosage transfer: process validation, analytical method transfer, stability studies and dossier preparation, delivered to the target country's GMP requirements.
After transfer, the supply relationship becomes long-term: recurring API purchases, milestone receipts and a share of dosage-form sales — a predictable cash return.
- Technology transfer fee
One-off, scoped case by case according to project complexity and registration scope.
- Milestone payments
Staged against completion of process validation, BE study passage and registration approval, keeping the partner's upfront exposure low.
- Royalty on sales
An agreed share of annual dosage-form sales after launch, tying our return to how the product actually performs.
- Supply linkage
Once transfer lands, API purchasing becomes recurring — supply and technology reinforce each other.
- Small and mid-size European formulators
They hold local market access and registration capability but lack a stable API source and a transfer partner, and want dosage-form capability fast.
- Emerging-market formulators
Driven by supply-chain security and localisation policy, they need a one-stop package of Chinese API plus technology transfer.
- Pipeline owners
Biotech and license-out parties that need overseas registration and commercial networks to license and land their pipelines.
Established commercial relationships with European and emerging-market formulators — a client entry point that pure transfer service providers cannot easily replicate.
Hands-on API-to-dosage transfer experience, process and analytical method transfer capability, and EU / US GMP registration compliance know-how.
A go-global dosage database and client management system that turns products, regulations, plants and buyers into a reusable information advantage.
Process validation protocol and report, analytical method transfer and confirmation, stability protocol and data, registration documentation prepared to target-country requirements (CTD modules), plus on-site support and Q&A through the transfer.
We do not claim every product can be transferred. Technical due diligence comes before signature: where transfer is feasible we state scope and milestones; where it is not, we say so plainly. Fees and milestone schedules follow the project review — there is no fixed price list.
The evidence you can request
We do not ask you to infer capability from a label. For a named product and market we confirm what actually exists.
Which legal entity contracts, which site manufactures, and what that site is qualified for.
Material specification, analytical data, and applicable regulatory records — listed as available, on request, or not yet available.
What we can send before any confidentiality agreement is in place.
What becomes available after a signed mutual confidentiality agreement, and how to request it.
Every item is confirmed per project. We do not publish confidential material, and we do not present a demonstration record as proof of delivery.
How fees work
We don't run a 'margin-only' model, and we don't hide fees inside quotes. Below are the possible charges, combined per the actual project.
| Item | Billing point | Description |
|---|---|---|
| Material supply | Per batch | A supply price that includes quality management and delivery assurance—not a simple buy-low/sell-high margin. |
| Custom development fee (FFS) | At project start | Scoped by route difficulty, step count and analytical effort—we quote hours and timeline before starting. |
| Tech package / process license | Per milestone | Settled as a lump sum or per milestone, arranged alongside the licensing deal. |
| Long-term supply framework | Annual | Unit price + minimum volume + price-adjustment mechanism, in exchange for capacity priority. |
| Tech transfer & audit support | Per service | Method transfer, on-site support, client-audit accompaniment and remediation follow-up. |
| Registration document services | Per project | DMF / CEP module compilation and lifecycle maintenance support. |
Final amounts and combinations follow the project quotation; there are no undisclosed extra charges.
Which tier to start at is your call
Tell us the product or CAS, the spec and quantity you need, and the target country—within 3 business days we return a technical-review conclusion and a commercial proposal. No long-term agreement up front, and no need to disclose your project on first contact.
Clear product and spec; I need a quote and lead time
Not in any catalog, or the spec can't be met
Need a second source, localization, or registration files
The cycles, barriers and deliverables on this page are typical ranges; the actual values follow the project's technical-review conclusion and contract. Matters involving registration and compliance are confirmed manually by the target-country authority and the compliance owner.